Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5702725	SPECGX LLC	Hydromorphone therapy	Jul, 2014 (9 years ago)
US5914131	SPECGX LLC	Hydromorphone therapy	Jul, 2014 (9 years ago)

Exalgo is owned by Specgx Llc.

Exalgo contains Hydromorphone Hydrochloride.

Exalgo has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Exalgo are:

Exalgo was authorised for market use on 01 March, 2010.

Exalgo is available in tablet, extended release;oral dosage forms.

Exalgo can be used as management of moderate to severe pain.

The generics of Exalgo are possible to be released after 07 July, 2014.

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Mar 01, 2013

Market Authorisation Date: 01 March, 2010

Treatment: Management of moderate to severe pain

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
8 mg and 12 mg	02 Sep, 2010	1	12 May, 2014	07 Jul, 2014	Deferred
16 mg	02 Aug, 2010	1	12 May, 2014	07 Jul, 2014	Deferred

Strength	Dosage	Availability
12MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
16MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
8MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued
32MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, EXTENDED RELEASE;ORAL	Discontinued

Exalgo patents expiration